NCT00982137 - Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

March 31, 2007

Conditions

Japanese EncephalitisYellow Fever

Interventions

BIOLOGICAL

Live attenuated Japanese encephalitis virus; Yellow fever virus

ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.

BIOLOGICAL

Yellow fever virus; Live attenuated Japanese encephalitis virus

STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.

BIOLOGICAL

Live attenuated Japanese encephalitis virus; Yellow fever virus

ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.

BIOLOGICAL

Live attenuated Japanese encephalitis virus; Yellow fever virus

Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.

Trial Locations (1)

Herston